In The News: June 2013

Oral tofacitinib (Xeljanz) has been shown to inhibit structural progression and joint damage in patients with rheumatoid arthritis (RA), according to an international phase III trial published in Arthritis & Rheumatism (March 2013). The 12-month analysis examined the effects of two years of treatment on joint preservation, RA disease activity and physical function in 797 patients with active disease, and at least three joint erosions or serologic evidence of rheumatoid factor or antibodies to cyclic citrullinated peptide.